Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm pivotal study of APG-2575 monotherapy in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
CTR20213084Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Suzhou Yasheng Pharmaceutical. Started Mar 2022; status: active.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20213084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213084.